Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.

Abstract

AIM:

To assess the efficacy and safety of sotagliflozin in patients with type 2 diabetes.

METHODS:

We searched Medline, Embase, the Cochrane Library, and grey literature sources up to August 2021 for randomized controlled trials (RCTs) that compared sotagliflozin with placebo or other antidiabetic agents in patients with type 2 diabetes. Our primary outcome was change in HbA1c from baseline. We additionally assessed three secondary efficacy and 15 safety outcomes. We synthesized data using weighted mean differences (WMDs) and odds ratios (ORs), along with 95% confidence intervals (CIs).

RESULTS:

We included 11 RCTs comprising 16 411 subjects in the meta-analysis. Compared with placebo, sotagliflozin reduced HbA1c (WMD -0.42%, 95% CI -0.56 to -0.29), body weight (WMD -1.33 kg, 95% CI -1.57 to -1.09), and systolic blood pressure (WMD -2.44 mmHg, 95% CI -2.81 to -2.07). No difference was evident against other active comparators. Sotagliflozin reduced myocardial infarction (OR 0.72, 95% CI 0.54 to 0.97) and heart failure (OR 0.68, 95% CI 0.58 to 0.79) compared with placebo, and had a neutral effect on all-cause mortality, cardiovascular mortality, and stroke. Treatment with sotagliflozin was safe regarding the incidence of serious adverse events, hypoglycaemia, and diabetic ketoacidosis. Nevertheless, it was associated with an increased incidence of diarrhoea, genital infections, and volume depletion events.

CONCLUSIONS:

Sotagliflozin reduces blood glucose, body weight, and systolic blood pressure, and demonstrates a beneficial effect on heart failure and myocardial infarction. Its overall safety profile is comparable with other sodium-glucose co-transporter-2 inhibitors.

• Authors: Ioannis Avgerinos, Thomas Karagiannis, Panagiota Kakotrichi, Theodoros Michailidis, Aris Liakos, David R Matthews, Apostolos Tsapas, Eleni Bekiari
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 24 Issue 1 Pg. 106-114 (01 2022) ISSN: 1463-1326 [Electronic] England
• PMID: 34545668 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
• Copyright: © 2021 John Wiley & Sons Ltd.

Chemical References

• Glycosides
• Hypoglycemic Agents
• Sodium-Glucose Transporter 2 Inhibitors
• (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

Topics

• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Glycosides (adverse effects)
• Humans
• Hypoglycemic Agents (adverse effects)
• Sodium-Glucose Transporter 2 Inhibitors (adverse effects)